Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)

[1]  D. Greenblatt,et al.  Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old , 2018, Antimicrobial Agents and Chemotherapy.

[2]  R. Calderón,et al.  Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis , 2017, Antimicrobial Agents and Chemotherapy.

[3]  B. Ledergerber,et al.  Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients , 2017, The Journal of antimicrobial chemotherapy.

[4]  A. Diacon,et al.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial , 2017, The Lancet. Infectious diseases.

[5]  A. Diacon,et al.  A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. , 2015, American journal of respiratory and critical care medicine.

[6]  C. Perno,et al.  Conference on Retroviruses and Opportunistic Infections 2015 , 2015, Journal of virus eradication.

[7]  D. Greenblatt,et al.  Isoniazid Mediates the CYP2B6*6 Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6 , 2014, Antimicrobial Agents and Chemotherapy.

[8]  W. Burman.  Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis , 2014, Morbidity and Mortality Weekly Report.

[9]  G. Makharia,et al.  Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  G. Maartens,et al.  Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. , 2012, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[11]  P. Hopewell,et al.  Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. Yip,et al.  Peak plasma rifampicin level in tuberculosis patients with slow culture conversion , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[13]  A. Diacon,et al.  Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears , 2007, Antimicrobial Agents and Chemotherapy.

[14]  Mikko Niemi,et al.  Pharmacokinetic Interactions with Rifampicin , 2003, Clinical pharmacokinetics.

[15]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[16]  C. Dolea,et al.  World Health Organization , 1949, International Organization.